Society of Dermatology Physician Assistants

At SDPA 2025, Mangin discussed her vitiligo approach, misconceptions, and how to determine when the disease is active.

In this interview at SDPA 2025, Hope Cook, PA-C, describes the contents of her talk regarding helping clinicians heal from burnout.

In this segment of her SDPA interview, Orit Markowitz, MD, highlights several points about dermoscopy, including common issues with identifying benign lesions.

More than 60% of patients with psoriasis achieved PASI 100 at week 16 with bimekizumab and maintained skin clearance up to 4 Years.

The topics of different hair textures and the management of alopecia in patients with skin of color were highlighted by Ginette Okoye, MD, at SDPA 2025.

Orit Markowitz, MD, highlighted takeaways from her SDPA presentation on the recognition of benign patterns in dermoscopy.

This interview at SDPA features Janelle Ball, founder and CEO of BC Educators, who discusses tips related to success with insurance authorizations.

Amlitelimab shows promise as a safe and effective treatment for moderate-to-severe atopic dermatitis, with sustained benefits post-treatment.

This interview segment at the 2025 SDPA Conference highlights additional insights by Friedman on the management and diagnosis of chronic hand eczema, or CHE.

In an interview conducted at the 2025 SDPA Conference, Friedman provided several insights into management and diagnosis of chronic hand eczema, or CHE.

At SDPA 2025, Candrice Heath, MD, said many clinicians remain unaware of baby perfume traditions that may contribute to persistent symptoms in patients of color.

At SDPA 2025, Candrice Heath, MD, presented on what you can do in your clinic to bridge the gap in pediatric atopic dermatitis among children with darker skin tones.

This session with Ginette Okoye, MD, features a discussion about hidradenitis suppurativa (HS) and several helpful approaches for patients.

Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, review a recent trial comparing upadacitinib to dupilumab for patients with atopic dermatitis.

Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, discuss recent data assessing ruxolitinib cream for patients as young as 2 years old with atopic dermatitis.

Patients in the spesolimab cohort demonstrated rapid improvements in DLQI scores compared with placebo, which were maintained through week 48.

Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.

Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.

Responses were highly durable throughout 4 years of bimekizumab treatment.

Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.

Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.

Significantly greater improvements were reported at week 2, which were sustained through week 12, in patients receiving the halobetasol propionate/tazarotene lotion compared with the vehicle cohort.

Overall, 189 (74.1%) patients treated with brodalumab achieved PASI 75, 133 (52.2%) achieved PASI 90, and 98 (38.4%) achieved PASI 100.

Lisa Swanson, MD, explains how building resiliency is crucial for coping with burnout.

Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.

Lisa Swanson, MD, discusses the pathogenesis of atopic dermatitis and why she does not recommend elimination diets for her pediatric patients.

Matthew Zirwas, MD, provides advice to dermatologists discussing the safety of JAK inhibitor therapies due to their controversial black box warning.

Patients with HS are getting a long-awaited influx of targeted therapies. Jennifer L. Hsiao, MD, discusses their immediate impact.

The new approval expands the treatment area by 4 times the previously approved area—from 25 cm2 to 100 cm2.